GlassScriptPhysician profile
Michael W Kent
NPI 1902084403
$17,297.92
in general payments reported to CMS, 2019-2025
9 companies · $9,626 in 2025
The $9,626 reported for 2025 was more than what 85% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2022: $297 · 2023: $220 · 2024: $6,950 · 2025: $9,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,940 · Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,215.00 |
| Travel and Lodging | $1,939.87 |
| Food and Beverage | $1,640.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $15,530.85 | 2024-2025 | Niktimvo, Niktimvo, Jakafi |
| Sobi, INC | $546.12 | 2022-2025 | |
| Mesoblast, INC. | $317.30 | 2025 | Ryoncil |
| Jazz Pharmaceuticals INC. | $302.05 | 2019-2023 | Defitelio |
| Vertex Pharmaceuticals Incorporated | $211.49 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $175.00 | 2025 | Ultomiris |
| Medexus Pharma, INC. | $164.87 | 2025 | Grafapex |
| Janssen Scientific Affairs, LLC | $50.24 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.